This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Clinical Insider
search
partnerships

Frontage teams with Medicover for genomics services

Posted by on 18 November 2024
Share this article

Frontage Laboratories has partnered with fellow trial services firm Medicover in a deal focused on the provision of genetic testing.

The partnership will see Frontage offer Medicover’s genomic analysis capabilities to customers that use its clinical trials services, according to Frontage president John Lin. Financial terms were not disclosed.

“We are pleased to announce this collaboration with Medicover Integrated Clinical Services (MICS). The collaboration aims to expand the global reach of both companies and will further and better support global clinical trials and clinical laboratory services.

“MICS will be the service partner with the genomic service capabilities to support clinical trials in Europe and will enhance our genomic service capabilities globally. Together, we will leverage our collective expertise to accelerate the development and commercialization of new therapies, ultimately benefiting the patients,” Lin said.

MICS head Apostolos Siscoglou commented, “Together, we aim to support our pharma and biotech partners by providing advanced and comprehensive genetic testing solutions on a global scale.”

MICS is a business unit of Nasdaq Nordic-listed testing supplier Medicover Diagnostic Services. The firm claims to operate a network of more than 100 laboratories in 13 countries. It provides central lab, site management, precision medicine, and companion diagnostics services to drug companies and contractors.

Frontage has been building in the genomic services space since 2021 when it acquired Ocean Ridge Biosciences, a provider of solutions for the analysis of RNA expression, DNA polymorphisms, methylation, microbial composition, and protein biomarkers.

And in January, Frontage appointed Qi Wei, former director of the CLIA laboratory at New Jersey precision medicine firm miR Scientific, as vice president of its global genomic services business.

Frontage has also been working to realign its broader business operations. In 2023 it established a discovery and development services unit and a separate laboratory services business, of which the genomics unit is a part.


Unsplash/Sangharsh Lohakare


Share this article

Sign up for Clinical Insider email updates

keyboard_arrow_down